目的：对比研究玻璃体腔注射康柏西普联合全视网膜激光光凝(PRP)与单纯全视网膜激光光凝对视网膜中央静脉阻塞(CRVO)继发Ⅰ、Ⅱ期新生血管性青光眼治疗效果的临床观察。

方法：采取临床病例对照研究方法。将2014-01/2019-03在我院诊断为CRVO继发Ⅰ、Ⅱ期新生血管性青光眼患者60例60眼，随机分为联合治疗组和单纯治疗组。联合治疗组采用康柏西普联合全视网膜激光光凝治疗； 单纯治疗组采用单纯全视网膜激光光凝治疗。观察两组患者治疗前、治疗后1wk，1、3、6、9mo的视力、眼压、虹膜新生血管、房角新生血管的情况，进行统计学分析。

结果：不同时间点两组房角及虹膜新生血管数量和视力、眼压有差异(F=154.992、92.519、30.696、82.374，均P<0.001)，联合治疗组在治疗开始后1wk的各项指标均出现明显好转，并维持至治疗结束。而单纯治疗组在给予治疗后数据改善程度不及联合治疗组(F=50.870、24.265、13.125、11.829，均P<0.001)。

结论：玻璃体腔注射康柏西普联合全视网膜激光光凝治疗CRVO继发Ⅰ、Ⅱ期新生血管性青光眼疗效优于单纯全视网膜激光光凝治疗，效果显著并持续维持。

METHODS: This was a prospective case-control study. Patients diagnosed with neovascular glaucoma(stage Ⅰor Ⅱ)secondary to CRVO in our hospital from January 2014 to March 2019 were enrolled and randomly divided into two groups. Patients in combination group were treated with both PRP and intravitreal conbercept injection. In the other group(PRP only group)patients were treated with PRP only. Changes of best corrected visual acuity(BCVA), intraocular pressure(IOP)and iris neovascularization(NVI)were observed before treatment, 1wk, 1mo, 3mo, 6mo and 9mo after treatment.

RESULTS: Sixty patients 60 eyes were enrolled, with the mean age of 54.45±6.08 years. 56.67% were males. There were no significant difference between two groups in age and gender. After treatment, all the indexes of the two groups improved obviously with significant different(F=154.992, 92.519, 30.696, 82.374, all P<0.001), visual acuity improved, IOP decreased, and NVI decreased at different time points. The difference was statistically significant compared with the control group one week after treatment(F=50.870, 24.265, 13.125, 11.829, all P<0.001), and it was maintained continuously.

CONCLUSION: For eyes with CRVO secondary with neovascular glaucoma, intravitreal injection of conbercept combined with panretinal photocoagulation PRP is better than panretinal photocoagulation PRP only.